Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

Summary

This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.

Timeline

Start

2014-09-29

Primary completion

2015-12-07

Completion

2015-12-07

Outcome

Met primary endpoint

registry Secukinumab vs Placebo; p <0.001; Difference between percentages 51 (95% CI 37 to 65) NCT02267135 ↗

release “In the SCALP study, PSSI 90 response rates were achieved by a significantly higher proportion of patients receiving Cosentyx vs. placebo at Week 12” novartis.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Secukinumab	Monoclonal antibody	300 mg	Subcutaneous

Indications